{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-016719","form_type":"8-K","ticker":"PPCB","cik":"0001517681","company_name":"Propanc Biopharma, Inc.","filed_at":"2025-06-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.577736+00:00","generated_at":"2026-05-18T15:49:05.374911+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Propanc Biopharma issues $67,860 convertible note with 35% conversion discount to 1800 Diagonal Lending","bullets":["Principal $67,860 for net $58,000; matures Apr 16, 2026; 15% one-time interest.","Conversion at 65% of lowest trading price in prior 10 days (35% discount); dilution risk.","Payments: $39,019.50 on Dec 15, 2025; then $9,754.88 on Jan 15, Feb 15, Mar 15, Apr 15, 2026.","Default triggers immediate acceleration; includes failure to pay, maintain OTC listing, or SEC reporting.","Proceeds for general working capital; note issued under Regulation D, not registered."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-016719","json":"https://secwatch.observer/filing/0001641172-25-016719.json","markdown":"https://secwatch.observer/filing/0001641172-25-016719.md","text":"https://secwatch.observer/filing/0001641172-25-016719.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517681/000164117225016719/0001641172-25-016719-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517681/000164117225016719/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T15:49:05.374911+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6cefcfa0cae3aaca1febeab89dfa6d21f9e47ac2","claim":"Propanc Biopharma, Inc. incurred convertible notes of $67,860.00 with an investor at one-time interest charge of fifteen percent (15%) maturing April 16, 2026.","evidence_excerpt":"with an investor (the “Investor”) pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $67,860.00 (the “Note”), for a purchase price of $58,000. The Company intends to use the net proceeds therefrom for general working capital purposes. The maturity date of the Note is April","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517681/000164117225016719/0001641172-25-016719-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$67,860.00"},{"label":"Counterparty","value":"an investor"},{"label":"Rate","value":"one-time interest charge of fifteen percent (15%)"},{"label":"Maturity","value":"April 16, 2026"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}